Kristi Rosa is an Associate Editorial Director at MJH Life Sciences. With a focus on medicine and healthcare, she covers a range of topics including oncology, hematology, immunotherapy, and gene therapy, among others. Kristi's work has been featured in prominent outlets such as CURE Media Group, Contagion_Live, and Oncology Nursing News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Kristi Rosa's articles predominantly cover healthcare and pharmaceutical topics, particularly focusing on the latest developments in cancer treatment. She frequently cites data to support her coverage, indicating a preference for evidence-based reporting.
Given her focus on clinical trial outcomes and drug approvals, she is likely to be interested in pitches featuring insights from medical professionals involved in these trials or experts with deep knowledge of the specific treatments or conditions being discussed. Additionally, she may appreciate pitches that provide access to exclusive data or analysis related to advancements in cancer research and treatment.
As Kristi does not have a specified geographic focus, sources with international perspectives or those involved in global clinical trials could be appealing for her articles covering various forms of cancer treatment.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Kristi Rosa
Adjuvant selpercatinib cut recurrence or death risk by 83% vs placebo in stage IB-IIIA RET fusion–positive NSCLC in LIBRETTO-432.
By: Kristi Rosa
Perioperative apalutamide plus ADT improved metastasis-free survival and pathologic responses in high-risk localized prostate cancer.
By: Kristi Rosa, Ashling Wahner
Seven-year data from the CROWN study show improved PFS with lorlatinib over crizotinib among patients with ALK-positive non–small cell lung cancer.
By: Kristi Rosa
FLAME data show ctDNA-guided addition of chemotherapy to osimertinib improved PFS vs osimertinib alone in EGFR-mutant NSCLC.
By: Kristi Rosa
Key Takeaways MonumenTAL-3 randomized 864 patients (1:1:1) to Tal-DP, Tal-D, or DPd, enrolling lenalidomide- and PI-exposed disease with ECOG 0–2; anti-CD38–refractory disease was excluded. PFS improved versus DPd (median 24.4 months): Tal-DP HR 0.28 and Tal-D HR 0.33, with 24‑month PFS 81.3% and 77.6%, respectively. Response quality increased materially: ORR ~88% with Tal-DP/Tal-D; ≥CR ~69%–71%; MRD-negative CR 46%–52% versus 15.9% with DPd. Benefit was consistent across high-risk subsets, including ≥75 years, prior daratumumab exposure, ISS stage III, high-risk cytogenetics, and soft-tissue plasmacytomas; first-relapse HRs were ~0.19–0.23. Safety reflected regimen composition: higher neutropenia and grade 3/4 infections with pomalidomide-containing arms; talquetamab arms had frequent mostly low-grade CRS, rare ICANS, and characteristic dysgeusia/skin-nail AEs with weight loss. SHOW MORE
By: Kristi Rosa
Epcoritamab improved PFS and produced durable complete responses vs chemoimmunotherapy in relapsed/refractory large B-cell lymphoma.
By: Kristi Rosa
Ziftomenib plus 7+3 yielded high CR and MRD-negativity rates with manageable safety in newly diagnosed NPM1/KMT2A-mutated AML.
Pumitamig plus chemotherapy generated strong responses across NSCLC subtypes and PD-L1 levels with manageable safety in ROSETTA Lung-02.
By: Kristi Rosa
Iza-bren improved PFS, OS, and response rates vs chemotherapy in pretreated metastatic TNBC, indicating a potential new standard of care.
By: Kristi Rosa
CHMP backs teclistamab plus daratumumab for earlier use in relapsed/refractory multiple myeloma following strong MajesTEC-3 results.
